GE launches e-commerce venture
In an effort to simplify the purchasing process for healthcare providers, GE Medical Systems has launched a series of electronic commerce offerings. The series initially is focusing on GE’s medical imaging accessories, x-ray equipment, and used
In an effort to simplify the purchasing process for healthcare providers, GE Medical Systems has launched a series of electronic commerce offerings. The series initially is focusing on GEs medical imaging accessories, x-ray equipment, and used devices. The site recommends accessories for six imaging modalities: CT, mammography, MRI, nuclear medicine, ultrasound, and x-ray. Site visitors can review product information for GEs x-ray line, and can purchase GEs AMX-4+ mobile radiography system or its Silhouette VR x-ray unit. Users can also view and select pre-owned equipment. The site is accessed through GEs home page and is refreshed every 12 hours. The Milwaukee-based firm plans to offer special pricing and service promotions regularly.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
